Lung Therapeutics is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis.In March 2021,Lung Therapeutics sold 715,000 shares and TFF Pharmaceuticals Inc had priced an offering.In June 2019, the company raised $36 million through series C financing and announced that it has raised a total of $53 million in outside funding.In June 2017, the company successfully raised $14.3 million through Series B financing. At that time, the company announced that it had raised $17 million through outside funding.In October 2014, the company raised $1,550,000 from the initial closing of a series A preferred stock of financing, including $550,000 in converted debt, and the remaining $1,200,000 committed to be funded upon achievement of certain milestones by the company with an additional milestone-driven commitments totaling upto $2,750,000